Factors associated with the clinical outcome of patients with relapsed/refractory CD19⁺ acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy.

ABSTRACT:

SUBMITTER: Ortiz-Maldonado V 

PROVIDER: S-EPMC8671976 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature